Plasmanex1™ a dietary supplement with the active ingredient Bacillopeptidase F Proprietary Blend (BFPB), a natural soy enzyme extracted by using a patented fermentation production process and shown to support healthy blood circulation, has been introduced to the health practitioner marketplace by Los Angeles-based Daiwa Health Development.
Plasmanex1™ has three primary functions, confirmed through several studies, including balancing blood flow through PAI-1 and t-PA, retarding thrombosis in abnormal coagulation states and decreasing blood viscosity through reduction of fibrinogen. The actions of preventing thrombus formation and decreasing blood viscosity make Plasmanex1™ unique.
“In vitro and in vivo studies suggest that Plasmanex1™ may reduce the unchecked production of PAI-1,” says Raif Tawakol, M.D., a cardiovascular surgeon in private practice with offices in Merced and Newport Beach, CA.
“In vivo studies have shown that Plasmanex1™ reduces other hypercoagulable factors to normal levels,” says Tawakol. “By reducing PAI-1 formation, plasmin/plasminogen is preserved, rather than increasing the formation of fibrin and fibrinogen and positions Plasmanex1™ as an effective Coagulation Modulator™,” adds Tawakol.
Recent studies revealed that Plasmanex1™ normalized the coagulation factors at various rates. Coagulation levels did not drop below normal levels with use of Plasmanex1™, yet by reducing production of pro-coagulant factors and reduction of unwanted wasted overuse of plasmin, it may be a desirable modulation of coagulation status.
“Eventually most, if not all, patient coagulation factors return to normal without a potential or a tendency towards excessive bleeding, that have resulted from a more balanced coagulation process, thus Plasmanex1™ assisted in the normalization of coagulation,” says Tawakol.
An in vitro study conducted at the Nagoya University of School of Medicine, Nagoya, Japan, suggests that Plasmanex1™ inhibits the production of PAI-1 in U87-MG cells in dose dependent manner.
In some studies on patients with acute coagulation changes, the use of Plasmanex1™ caused an increase in t-PA activity, an enzyme which acts to rapidly break down newly formed blood clots in the blood vessels, and promotes plasmin viability. High C-reactive protein levels in patients were reduced, indicating a reduction in vascular inflammation or excessive lipid accumulation which correlated with decreased PAI-1 activity. This activity led to increased t-PA levels, ultimately increasing clot dissolution activity. Plasmanex1™ restored the PAI-1/t-PA balance and lowered overall clot levels of fibrin and fibrin degradation products.
As a dietary supplement, the recommended dosage for Plasmanex1™ is one or two capsules before bedtime, or one in the morning and one at night. One capsule a day is recommended when Plasmanex1™ is used chronically and a possible history of bleeding exists.
Daiwa Pharmaceutical Co., Ltd., Tokyo, Japan, the parent company of Daiwa Health Development Inc. U.S.A., has applied for U.S. Patent Application No. 20060105071 referencing the BFPB as a blood viscosity reducing agent. Daiwa also has filed a patent 2004-331559 in Japan for BFPB as a blood viscosity reducing agent
Daiwa Health Development, Inc., a subsidiary of Daiwa Pharmaceutical Co. Ltd. based in Tokyo, Japan, has become a leading research and manufacturing company, striving to create new value in the field of bioscience. Daiwa Health Development also manufactures and distributes BRM4™, a patented immune enhancing complex with Rice Bran Arabinoxylan Compound that has been clinically shown to triple “Natural Killer cell” activity, increase T and normalize B cell lymphocytes and demonstrate vital antioxidant and anti-inflammatory action.
For complete Plasmanex1™ study information and in-office health practitioner product sales, contact Daiwa Health Development at 877.434.3633 or by email at [email protected].